Authors as listed in the Journal of Affective Disorders record, 2024-07-15: Single-blinded randomized crossover MRI study in 15 euthymic bipolar I patients and 15 matched controls receiving intravenous methylene blue 0.5 mg/kg or placebo, measuring cerebral blood flow, oxygen extraction and metabolic rate of oxygen.
each after intravenous infusion of either MB (0.5 mg/kg) or placebo
abstract
Authors as listed in the Journal of Affective Disorders record, 2024-07-15: Single-blinded randomized crossover MRI study in 15 euthymic bipolar I patients and 15 matched controls receiving intravenous methylene blue 0.5 mg/kg or placebo, measuring cerebral blood flow, oxygen extraction and metabolic rate of oxygen. Study type: single-blinded randomized crossover physiological neuroimaging study (mechanistic, not a treatment trial). N=30 (15 bipolar I patients, 15 healthy controls). Country: not stated in abstract (authors from a UK/US neuroimaging group). Dose/route: 0.5 mg/kg intravenous, single infusion. Comparator: placebo infusion. Funder/conflicts: not stated in abstract. Shows a divergent neurometabolic response in bipolar patients – supports a mechanistic rationale, not clinical efficacy. Study type: randomized trial.
